IBI-3004
- Generic Name
- IBI-3004
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT06198426
- Locations
- 🇦🇺
Liverpool Hospital, Sydney, New South Wales, Australia
🇦🇺Westmead Hospital, Sydney, New South Wales, Australia
🇨🇳Jiang Su Province Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath